Phost'in Therapeutics
- Biotech or pharma, therapeutic R&D
Phost’in Therapeutics is a clinical-stage biotech developing first-in-class N-glycosylation inhibitors as targeted therapies for solid tumors and fibrotic diseases. A first-in-human trial for lead program PhOx430, a selective GnT-V inhibitor, began in 2022. Phase I (dose escalation) was completed in 2024 with 21 patients, confirming safety, target engagement, and preliminary signs of activity (TIL increase / tumor response). The program is available for global licensing.
In parallel, Phost’in leverages its proprietary Phost’screen™ discovery platform to generate a new generation of glycosylation-targeting assets, with a strong focus on fibrotic indications.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}